TY - JOUR
T1 - Femtosecond infrared laser - An efficient and safe in vivo gene delivery system for prolonged expression
AU - Zeira, Evelyne
AU - Manevitch, Alexandra
AU - Khatchatouriants, Artium
AU - Pappo, Orit
AU - Hyam, Esti
AU - Darash-Yahana, Merav
AU - Tavor, Einat
AU - Honigman, Alik
AU - Lewis, Aaron
AU - Galun, Eithan
N1 - Funding Information:
We thank Dina Ben-Yehuda for her scientific support. This study was supported by a grant from the Israeli Ministry of Science, the San-Francisco Jewish Federation, the Blum Foundation, and the Sylvia and Martin Snow Charitable Foundation.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - The major advantages of "naked DNA gene therapy" are its simplicity and a low or negligible immune response. Gene delivery by DNA electroporation (EP) involves injection of DNA and the application of a brief electric pulse to enhance cellular permeability. Although EP is an efficient gene transduction technique in rodents, it requires much higher voltages (>500 V) in larger animals, and hence, in practice it would be hazardous for human patients, as it would cause serious tissue damage. To overcome the obstacles associated with EP-mediated gene delivery in vivo, we developed a new method of gene transduction that uses laser energy. The femtosecond infrared titanium sapphire laser beam was developed specifically for enhancing in vivo gene delivery without risks of tissue damage. System optimization revealed that injection of 10 μg naked DNA into the tibial muscle of mice followed by application of the laser beam for 5 s, focused to 2 mm depth upon an area of 95 × 95 μm2, resulted in the highest intensity and duration of gene expression with no histological or biochemical evidence of muscle damage. We assessed the potential clinical application of LBGT technology by using it to transfer the murine erythropoietin (mEpo) gene into mice. LBGT-mediated mEpo gene delivery resulted in elevated (>22%) hematocrit levels that were sustained for 8 weeks. Gene expression following LBGT was detected for > 100 days. Hence, LBGT is a simple, safe, effective, and reproducible method for therapeutic gene delivery with significant clinical potential.
AB - The major advantages of "naked DNA gene therapy" are its simplicity and a low or negligible immune response. Gene delivery by DNA electroporation (EP) involves injection of DNA and the application of a brief electric pulse to enhance cellular permeability. Although EP is an efficient gene transduction technique in rodents, it requires much higher voltages (>500 V) in larger animals, and hence, in practice it would be hazardous for human patients, as it would cause serious tissue damage. To overcome the obstacles associated with EP-mediated gene delivery in vivo, we developed a new method of gene transduction that uses laser energy. The femtosecond infrared titanium sapphire laser beam was developed specifically for enhancing in vivo gene delivery without risks of tissue damage. System optimization revealed that injection of 10 μg naked DNA into the tibial muscle of mice followed by application of the laser beam for 5 s, focused to 2 mm depth upon an area of 95 × 95 μm2, resulted in the highest intensity and duration of gene expression with no histological or biochemical evidence of muscle damage. We assessed the potential clinical application of LBGT technology by using it to transfer the murine erythropoietin (mEpo) gene into mice. LBGT-mediated mEpo gene delivery resulted in elevated (>22%) hematocrit levels that were sustained for 8 weeks. Gene expression following LBGT was detected for > 100 days. Hence, LBGT is a simple, safe, effective, and reproducible method for therapeutic gene delivery with significant clinical potential.
KW - Electroporation
KW - Gene expression in vivo
KW - Gene therapy
KW - Naked DNA
KW - Nonviral vectors
UR - http://www.scopus.com/inward/record.url?scp=10744227154&partnerID=8YFLogxK
U2 - 10.1016/S1525-0016(03)00184-9
DO - 10.1016/S1525-0016(03)00184-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 12907157
AN - SCOPUS:10744227154
SN - 1525-0016
VL - 8
SP - 342
EP - 350
JO - Molecular Therapy
JF - Molecular Therapy
IS - 2
ER -